The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

被引：0

作者：

Al-Sawaf, Othman ^{[1
,2
,3
]}

Fuerstenau, Moritz ^{[1
,2
,3
]}

Giza, Adam ^{[1
,2
,3
]}

Robrecht, Sandra ^{[1
,2
,3
]}

Von Tresckow, Julia ^{[4
]}

Fink, Anna Maria ^{[1
,2
,3
]}

Simon, Florian ^{[1
,2
,3
]}

Tausch, Eugen ^{[5
]}

Schneider, Christof ^{[6
]}

Sivcheva, Liliya ^{[7
]}

Schwarer, Anthony ^{[8
]}

Loscertales, Javier ^{[9
]}

Weinkove, Robert ^{[10
]}

Strumberg, Dirk ^{[11
]}

Kilfoyle, Allanah R. ^{[12
]}

Juliusson, Gunnar ^{[13
]}

Da Cunha-Bang, Caspar ^{[14
]}

Illmer, Thomas

Gregor, Michael ^{[15
]}

Thornton, Patrick ^{[16
]}

Janssens, Ann ^{[17
]}

Tadmor, Tamar ^{[18
]}

Lindstrom, Vesa ^{[19
,20
]}

Staber, Philipp Bernhard ^{[21
]}

Levin, Mark-David ^{[22
]}

Wendtner, Clemens-Martin ^{[23
]}

Kreuzer, Karl-Anton ^{[1
,2
,3
]}

Ritgen, Matthias ^{[24
]}

Stilgenbauer, Stephan ^{[25
]}

Kater, Arnon P. ^{[26
]}

Niemann, Carsten Utoft ^{[27
]}

Fischer, Kirsten ^{[1
,2
,3
]}

Eichhorst, Barbara F. ^{[28
]}

Hallek, Michael ^{[29
]}

机构：

[1] Univ Cologne, Fac Med, Cologne, Germany

[2] Univ Cologne, Univ Hosp Cologne, Dept Internal Med 1, Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Cologne, Germany

[3] Univ Cologne, German CLL Study Grp, Cologne, Germany

[4] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Clin Hematol & Stem Cell Transplantat, Essen, Germany

[5] Ulm Univ, Div CLL, Dept Internal Med 3, Ulm, Germany

[6] Univ Ulm, Div CLL, Dept Internal Med 3, Ulm, Germany

[7] Multiprofile Hosp Act Treatment HristoBotev, Dept Internal Med 1, Vratsa, Bulgaria

[8] Box Hill Hosp, Melbourne, Vic, Australia

[9] Hosp Univ La Princesa, Madrid, Spain

[10] Wellington Rerenga Ora Blood & Canc Ctr, Capital & Coast Dist Hlth Board, Wellington, New Zealand

[11] Marien Hosp, Herne, Germany

[12] Palmerston North Hosp, Palmerston North, New Zealand

[13] Lund Univ Canc Ctr, Dept Hematol, Lund, Sweden

[14] Rigshosp, Copenhagen, Denmark

[15] Cantonal Hosp Lucerne, Div Hematol, Luzern, Switzerland

[16] Beaumont Hosp, Canc Trials Ireland, Dept Haematol, RCSI, Dublin, Ireland

[17] Univ Hosp Leuven, Leuven, Belgium

[18] Bnai Zion Med Ctr, Hematol, Haifa, Israel

[19] Helsinki Univ Hosp, Dept Hematol, Ctr Comprehens Canc, Helsinki, Finland

[20] Univ Helsinki, Helsinki, Finland

[21] Med Univ Vienna, Div Hematol & Hemostaseol, Dept Med 1, Vienna, Austria

[22] Albert Schweitzer Hosp, Dept Internal Med, Dordrecht, Netherlands

[23] German CLL Study Grp, Munich Clin Schwabing, Dept Hematol Oncol Immunol Palliat Care Infect Di, Munich, Germany

[24] Univ Schleswig Holstein, Dept Internal Med 2, Kiel, Germany

[25] Univ Hosp Ulm, Div CLL, Dept Internal Med 3, Ulm, Germany

[26] Acad Med Ctr, Amsterdam, Netherlands

[27] Copenhagen Univ Hosp, Dept Hematol, Rigshosp, Copenhagen, Denmark

[28] Univ Cologne, Cologne, Germany

[29] Univ Hosp Cologne, Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Cologne, Germany

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-188827

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：8

共 50 条

[1] Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia
Flinn, Ian W.
Gribben, John G.
Dyer, Martin J. S.
Wierda, William
Maris, Michael B.
Furman, Richard R.
Hillmen, Peter
Rogers, Kerry A.
Iyer, Swaminathan Padmanabhan
Quillet-Mary, Anne
Ysebaert, Loic
Walter, Harriet S.
Verdugo, Maria
Klein, Christian
Huang, Huang
Jiang, Yanwen
Lozanski, Gerard
Pignataro, Daniela Soriano
Humphrey, Kathryn
Mobasher, Mehrdad
Kipps, Thomas J.
BLOOD, 2019, 133 (26) : 2765 - 2775
[2] Venetoclax-Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia: 5-Year Results of the Randomized CLL14 Study
Al-Sawaf, Othman
Zhang, Can
Robrecht, Sandra
Kotak, Alex
Chang, Naomi
Fink, Anna
Tausch, Eugen
Schneider, Christof
Ritgen, Matthias
Kreuzer, Karl
Chyla, Brenda
Eichhorst, Barbara
Jiang, Yanwen
Stilgenbauer, Stephan
Hallek, Michael
Fischer, Kirsten
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S274 - S275
[3] Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study
Al-Sawaf, Othman
Robrecht, Sandra
Zhang, Can
Olivieri, Stefano
Chang, Naomi
Fink, Anna
Tausch, Eugen
Ritgen, Matthias
Kreuzer, Karl
Sivcheva, Lilly
Niemann, Carsten
Schwarer, Anthony
Loscertales, Javier
Weinkove, Robert
Strumberg, Dirk
Kilfoyle, Allanah
Runkel, Eva
Eichhorst, Barbara
Stilgenbauer, Stephan
Jiang, Yanwen
Hallek, Michael
Fischer, Kirsten
LEUKEMIA & LYMPHOMA, 2023, 64 : S113 - S113
[4] Obinutuzumab for previously untreated chronic lymphocytic leukemia
不详
JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2014, 12 (04): : 118 - 120
[5] Preliminary Safety and Efficacy Results From a Phase 2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Awan, Farrukh T.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 6 - 8
[6] Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia
Gay, Nathan D.
Kozin, Eliana
Okada, Craig
Danilov, Alexey V.
Spurgeon, Stephen
LEUKEMIA & LYMPHOMA, 2018, 59 (09) : 2258 - 2260
[7] Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study
Al-Sawaf, Othman
Robrecht, Sandra
Zhang, Can
Olivieri, Stefano
Chang, Yi Meng
Fink, Anna Maria
Tausch, Eugen
Schneider, Christof
Ritgen, Matthias
Kreuzer, Karl-Anton
Sivchev, Liliya
Niemann, Carsten Utoft
Schwarer, Anthony
Loscertales, Javier
Weinkove, Robert
Strumberg, Dirk
Kilfoyle, Allanah
Manzoor, Beenish S.
Jawaid, Dureshahwar
Emechebe, Nnadozie
Devine, Jacob
Boyer, Michelle
Runkel, Eva D.
Eichhorst, Barbara
Stilgenbauer, Stephan
Jiang, Yanwen
Hallek, Michael
Fischer, Kirsten
BLOOD, 2024, 144 (18) : 1924 - 1935
[8] Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Lampson, Benjamin L.
Tyekucheva, Svitlana
Crombie, Jennifer L.
Kim, Austin I.
Merryman, Reid W.
Lowney, Jessica
Montegaard, Josie
Patterson, Victoria
Jacobson, Caron A.
Jacobsen, Eric D.
LaCasce, Ann S.
Arnason, Jon E.
Armand, Philippe
Fisher, David C.
Brown, Jennifer R.
Davids, Matthew S.
BLOOD, 2019, 134
[9] Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia
Hill, Brian T.
Kalaycio, Matt
ONCOTARGETS AND THERAPY, 2015, 8 : 2391 - 2397
[10] COST-EFFECTIVENESS OF OBINUTUZUMAB IN PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA
Reyes, C.
Gazauskas, G.
Veentra, D.
ANNALS OF ONCOLOGY, 2014, 25

← 1 2 3 4 5 →